News | Heart Failure | December 09, 2015

BioVentrix Announces First Pre-Clinical Use of Revivent-TC System

Study demonstrates feasibility of implantation of anchoring technology via a catheter-based approach from within the left ventricle to treat heart failure

BioVentrix, Revivent-TC System, pre-clinical, Louis Labrousse, Hopital Haut-Leveque

Image courtesy of BioVentrix

December 9, 2015 — BioVentrix Inc. has achieved the first implantation of its micro-anchor heart failure (HF) technology from entirely within the left ventricle (LV) using a catheter-based endovascular approach. This milestone was realized in collaboration with Prof. Louis Labrousse, chief of cardiovascular surgery at Hopital Haut-Leveque in Bordeaux-Pessac France. The pre-clinical study was performed in a previously infarcted ovine model which replicates the scar tissue and anatomy observed in human subjects following a myocardial infarction. The new technology proved it is feasible to identify post-ischemic scar tissue, access the scar from within the vasculature, and deploy Revivent micro-anchors to exclude the diseased tissue without opening the chest.

"The next generation of the Revivent therapy represents a tremendous advancement towards a fully percutaneous volume reduction procedure for heart failure patients. The new system will vastly improve the accuracy of anchor placement and enable a more minimally invasive approach," said Labrousse. He has previously served as principal investigator of numerous other clinical studies seeking to treat patients with the complex challenge of ischemic heart failure.

BioVentrix has shown that the exclusion of scar tissue from the LV cavity in patients suffering from ischemic cardiomyopathy heart failure results in substantial improvements in Quality of Life. This study demonstrates the ability to accomplish the same outcomes with the current hybrid approach. The company anticipates this next-generation system will be utilized in clinical trials in early 2016.

Placement of the Revivent-TC System via the LIVE procedure obviates the need for more invasive surgery. Instead, small titanium anchors are placed along the outer surface of the heart and along one of the interior walls via a closed-chest, transcatheter approach. The anchors are then pulled toward one another, effectively excluding the scarred and non-functioning heart wall. Ventricular volume is immediately reduced as a result of the exclusion, by as much as 30-40 percent.

For more information: www.bioventrix.com

Related Content

Videos | Cath Lab | August 13, 2018
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott While Heart and Vascul
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal c
Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used
Recent Acquisitions Eroding Prices in Billion Dollar European Interventional Cardiology cath lab Market.
Feature | Cath Lab | May 07, 2018 | Simon Trinh and Jeffrey Wong
The European interventional cardiology market is currently valued at nearly $1.4 billion.
Videos | Cath Lab | May 07, 2018
Imran Ahmad, M.D., medical director of interventional cardiology, explains some of the new technologies his labs have
360 Photos | Cath Lab | April 20, 2018
A 360 degree view of the newest cath lab at Northwestern Medicine Central DuPage Hospital in Winfield, Ill., located
SCAI Announces Global Lecture Series for 2018 Scientific Sessions
News | Cath Lab | April 18, 2018
Many of the world’s leading interventional cardiologists and cardiovascular professionals will convene in San Diego,...
Overlay Init